脊椎生物製剤市場レポート：製品、手術タイプ、エンドユーザー、地域別、2024～2032年

世界の脊椎生物製剤市場規模は2023年に21億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに29億米ドルに達し、2024～2032年の間に3.7％の成長率（CAGR）を示すと予測しています。この市場を牽引しているのは、低侵襲手術（MIS）の普及、高齢者人口の増加、所得水準の上昇に伴う医療サービスへのアクセスの増加、脊椎疾患の罹患率の増加です。

脊椎生物製剤市場分析

主要市場促進要因：脊椎生物製剤市場の調査によると、市場は主に椎間板疾患や脊柱管狭窄症などの脊椎疾患の有病率の増加によって牽引されており、多くの場合、加齢やライフスタイル要因に関連しています。

主要市場動向：医療技術の進歩に伴い、早期回復とより良い治療成績を促進するため、脊椎手術に生物製剤を使用する傾向が顕著です。脊椎生物製剤市場予測では、脊椎生物製剤の精度と有効性を高める人工知能と機械学習技術の統合により、業界は継続的なイノベーションを確認します。

地理的動向：北米は、高度な医療インフラ、高額な医療費、脊椎疾患に対する認識により、現在世界市場をリードしています。さらに、アジア太平洋は、医療アクセスの増加、経済水準の向上、高齢者人口の増加により、脊椎生物製剤市場統計によると急成長を遂げています。

競合情勢：脊椎生物製剤業界の主要市場参入企業には、Arthrex Inc.、Alphatec Holdings Inc.、Exactech Inc.、Johnson &Johnson、Medtronic plc、NuVasive Inc.、Orthofix Medical Inc.、Stryker Corporation、Wright Medical Group N.V.、Zimmer Biometなどがあります。

課題と機会：市場課題には、生物製剤の高コストに対する懸念や、製品上市を遅らせる可能性のある厳しい規制環境などがあります。脊椎生物製剤市場概要で説明したように、保険業者や医療施設との協力関係の拡大は、生物製剤による治療へのアクセスや取り込みを改善し、多くの機会を生み出す可能性を秘めています。

脊椎生物製剤市場の動向

脊椎疾患の有病率の増加

脊椎疾患の増加が脊椎生物製剤市場の成長に影響を与えています。加えて、平均寿命の伸びやライフスタイルの問題が、椎間板疾患や脊柱管狭窄症などの退行性疾患の発症に拍車をかけています。世界保健機関（WHO）によると、2020年には約13人に1人、6億1,900万人が腰痛（LBP）を経験し、1990年から60％増加するといいます。さらに、2050年までに腰痛症例は約8億4,300万人増加すると推定されており、脊椎の問題が広範囲に及んでいることが強調されています。罹患者数が増加しているのは80歳代であり、LBPの罹患者数が増加しているのは50～55歳代です。このような広範な有病率から、骨の成長と治癒を促進する生物製剤を含む効果的な治療法の継続的な開発と展開が必要とされ、このような広範な症状の治療には生物製剤が不可欠となっています。

低侵襲手術（MIS）の採用増加

脊椎疾患に対する低侵襲手術（MIS）は、従来の開腹手術に比べて苦痛が少なく、回復が早いため好まれています。IMARC GROUPによると、低侵襲手術の世界市場は、2024～2032年にかけて約6％の複合年間成長率（CAGR）で拡大すると予測されています。2023年には529億米ドルに達し、2032年には910億米ドルに達すると予測しています。この成長は、特に脊椎生物製剤市場の価値にとって有益な、入院期間と回復期間を短縮する手術方法のシフトを宣言しています。

高齢者人口の増加

高齢者人口の増加が脊椎生物製剤市場の需要を牽引しています。高齢になるにつれて、脊椎障害を発症するリスクは増加し、より頻繁で集中的な治療が必要となります。国連のデータによると、65歳以上の人口は2022年の10%から2050年には16%に増加すると予想されています。世界の65歳以上の人口は、5歳以下の子どもの数の2倍になり、12歳の子どもの数に匹敵すると予測されています。これは、加齢に伴う脊椎疾患の増加を意味し、効果的で低侵襲な治療に対する需要が高まっています。例えば、自然治癒プロセスを助ける生物製剤は、高齢化する世界人口の増加する医療要件に合致し、こうしたニーズに応えるのに特に適しています。

脊椎生物製剤市場セグメンテーション

IMARC Groupは、市場の各セグメントにおける主要動向の分析と、2024～2032年までの世界、地域、国レベルの予測を提供しています。製品タイプ、手術タイプ、エンドユーザー別に市場を分類しています。

製品別内訳

骨移植代替物が市場シェアの大半を占める

本レポートでは、製品別に市場を詳細に区分・分析しています。これには、脊椎移植片（機械加工骨移植片、脱灰骨マトリックス）、骨移植片代替品、（骨形態形成タンパク質、合成骨移植片）、細胞ベースマトリックスが含まれます。報告書によると、骨移植代替物は最大のセグメントを占めています。

骨移植代替物は、慣習的な骨移植に代わるものを提供し、脊椎手術における構造的支持を規定し、骨治癒プロセスを促進します。これらの代用品には、合成材料、同種移植片、脱灰骨マトリックスなどがあり、骨融合を支持し、患者自身の体から骨を採取する必要性を抑制し、外科的合併症や回復時間を最小限に抑える適性があるとして提唱されています。IMARC GROUPの統計によると、世界の骨移植片と代替物市場は2023年に32億米ドルに達しました。2024～2032年の年間平均成長率（CAGR）は5.2％で、2032年には51億米ドルに達すると推定されています。さらに、生体材料、再生医療、骨移植代替物における様々な進歩は、脊椎手術における採用の増加を目の当たりにしており、脊椎生物製剤の市場規模を積極的に高めています。

手術タイプ別内訳

低侵襲脊椎手術が業界最大シェアを占める

本レポートでは、手術タイプ別の市場の詳細な区分と分析も行っています。これには、開放脊椎手術と低侵襲脊椎手術が含まれます。同レポートによると、低侵襲脊椎手術が最大の市場シェアを占めています。

低侵襲脊椎手術は、主に患者や医療プロバイダーの間で低侵襲手順への嗜好が高まっていることに起因しています。低侵襲脊椎手術は、従来の開腹手術に比べ、切開創の縮小、出血量の減少、入院期間の短縮、回復時間の短縮など、いくつかの利点があります。その結果、椎間板変性症、椎間板ヘルニア、脊柱管狭窄症、椎体骨折など、さまざまな脊椎疾患の治療に人気を博しています。NATIONAL LIBRARY OF MEDICINEによると、低侵襲脊椎（MIS）手術は、画像ナビゲーションシステム、ロボット工学、内視鏡によって大きく進歩しました。米国では年間40万件以上の治療が行われており、脊椎固定術は脊椎の外傷、腫瘍、構造的変形、退行性疾患に対して一般的に行われ、確立された治療法です。

エンドユーザー別内訳

病院が市場の主要セグメントを占める

本レポートでは、市場をエンドユーザー別に詳細に区分・分析しています。これには、病院、外来ケアセンター、脊椎手術センター、整形外科クリニック、その他が含まれます。報告書によると、病院が最大のセグメントを占めています。

病院は専門的な医療を提供する主要なセンターであり、手術を必要とする脊椎疾患を含む様々な脊椎疾患の治療を求める患者がかなりの割合で訪れます。さらに、一部の病院では脊椎専門センターや診療科を設けており、総合的な脊髄治療の拠点として好まれています。これに加えて、病院は脊椎生物製剤メーカーやサプライヤーと強力な協力関係を結んでおり、それによって機器の効率性を高めています。2022年6月、Xenco Medicalは、食品医薬品局（FDA）の認可を取得し、外来手術センター向けの機器の幅を広げ、単独使用のためのMultilevel CerviKitを発表しました。これは、前頚椎の2レベル、3レベル、4レベル手術用のインプラントと使い捨て器具一式で構成されています。

地域別内訳

北米が市場をリードし、最大の脊椎生物製剤市場シェアを占める

本レポートでは、北米（米国、カナダ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他）、アジア太平洋（中国、日本、インド、韓国、オーストラリア、インドネシア、その他）、ラテンアメリカ（ブラジル、メキシコ、その他）、中東アフリカの主要地域市場についても包括的に分析しています。同レポートによると、脊椎生物製剤の最大地域市場は北米です。

北米が同市場において優位を占めているのは、高度に発達した医療インフラ、革新的医療技術の採用率の高さ、脊椎疾患の患者数の多さなどに起因しています。例えば、全米脊髄損傷協会のデータによると、米国には約45万人の脊髄損傷（SCI）患者がいます。毎年、推定1万7,000人の脊髄損傷患者が新たに発生しており、その主要原因は脊椎の外傷です。このように、SCI患者の増加は、地域全体の障害を治療するための脊椎生物製剤の需要を著しく高めています。さらに、好意的な償還政策、強力な研究開発努力、低侵襲外科手術の利点に対する認識が、北米の脊椎生物製剤市場収益を生み出しています。

競合情勢

脊椎生物製剤市場調査レポートは、市場の競合情勢についても包括的に分析しています。すべての主要企業の詳細プロファイルも提供しています。脊椎生物製剤業界の主要市場企業には、Arthrex Inc.、Alphatec Holdings Inc.、Exactech Inc.、Johnson &Johnson、Medtronic plc、NuVasive Inc.、Orthofix Medical Inc.、Stryker Corporation、Wright Medical Group N.V.、Zimmer Biometなどがあります。

（これは主要参入企業の一部一覧であり、完全なリストは報告書に記載されていることに留意されたい）。

現在、同市場の主要参入企業は、ライバルを凌駕し、顧客が求めるソリューションを提供するモデルを開発するため、研究開発とイノベーションに投資しています。また、より多くの市場に参入し、あらゆる顧客のニーズに応えるために、戦略的提携の開拓、買収、新市場への進出などを通じて、自社製品が確実に市場に残り、顧客の需要を満たすよう努めています。例えば、2023年10月、世界的に著名な脊椎・整形外科企業であるOrthofix Medical Inc.は、革新的な生体活性合成移植片であるOsteoCoveの完全商業リリースを発表しました。オステオコーブは、パテとストリップの形態で提供され、様々な脊椎・整形外科手術において卓越した骨形成能力と最適な取り扱い特性を提供するために綿密に開発されました。さらに、優れたマーケティングとブランド管理により、同社製品の需要は高く、脊椎生物製剤市場展望は明るいです。

脊椎生物製剤市場ニュース

2022年8月：Graftys SAは、Arthrexとの高度合成骨移植材に関する複数年供給契約の更新を発表。

2023年10月：著名な医療技術企業であるStrykerは、脊椎ガイダンスソフトウェアを搭載したQガイダンスシステムを発表しました。

本レポートで扱う主要質問

• 世界の脊椎生物製剤の規模は？
• 2024～2032年における脊椎生物製剤市場の成長率は？
• 世界の脊椎生物製剤市場を牽引する主要要因は何か
• 世界の脊椎生物製剤市場に対するCOVID-19の影響は？
• 脊椎生物製剤市場の製品別内訳は？
• 世界の脊椎生物製剤市場の手術タイプ別内訳は？
• 世界の脊椎生物製剤市場のエンドユーザー別の内訳は？
• 脊椎生物製剤市場の世界における主要地域は？
• 世界の脊椎生物製剤市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界の脊椎生物製剤市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：製品別

• 脊椎同種移植
  • 市場動向
  • 主要セグメント
    • 機械加工骨同種移植
    • 脱灰骨基質
  • 市場予測
• 骨移植代替品
  • 市場動向
  • 主要セグメント
    • 骨形成タンパク質
    • 人工骨移植
  • 市場予測
• 細胞ベースマトリックス

第7章 市場内訳：手術タイプ別

• 脊椎開放手術
• 低侵襲脊椎手術

第8章 市場内訳：エンドユーザー別

• 病院
• 外来診療センター
• 脊椎手術センター
• 整形外科クリニック
• その他

第9章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第10章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Arthrex Inc
  • Alphatec Holdings Inc.
  • Exactech Inc
  • Johnson & Johnson
  • Medtronic plc
  • NuVasive Inc
  • Orthofix Medical Inc.
  • Stryker Corporation
  • Wright Medical Group N.V.
  • Zimmer Biomet

List of Figures

• Figure 1: Global: Spine Biologics Market: Major Drivers and Challenges
• Figure 2: Global: Spine Biologics Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Spine Biologics Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 4: Global: Spine Biologics Market: Breakup by Product (in %), 2023
• Figure 5: Global: Spine Biologics Market: Breakup by Surgery Type (in %), 2023
• Figure 6: Global: Spine Biologics Market: Breakup by End User (in %), 2023
• Figure 7: Global: Spine Biologics Market: Breakup by Region (in %), 2023
• Figure 8: Global: Spine Biologics (Spinal Allografts) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 9: Global: Spine Biologics (Spinal Allografts) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 10: Global: Spine Biologics (Bone Graft Substitutes) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 11: Global: Spine Biologics (Bone Graft Substitutes) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 12: Global: Spine Biologics (Cell Based Matrix) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 13: Global: Spine Biologics (Cell Based Matrix) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 14: Global: Spine Biologics (Open Spine Surgery) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: Spine Biologics (Open Spine Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: Spine Biologics (Minimally Invasive Spine Surgery) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: Spine Biologics (Minimally Invasive Spine Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: Spine Biologics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: Spine Biologics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: Global: Spine Biologics (Ambulatory Care Centers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: Global: Spine Biologics (Ambulatory Care Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Global: Spine Biologics (Spinal Surgery Centers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Global: Spine Biologics (Spinal Surgery Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Global: Spine Biologics (Orthopedic Clinics) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 25: Global: Spine Biologics (Orthopedic Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 26: Global: Spine Biologics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 27: Global: Spine Biologics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 28: North America: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 29: North America: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 30: United States: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 31: United States: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 32: Canada: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 33: Canada: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 34: Asia-Pacific: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 35: Asia-Pacific: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 36: China: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 37: China: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 38: Japan: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 39: Japan: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 40: India: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 41: India: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 42: South Korea: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 43: South Korea: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 44: Australia: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 45: Australia: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 46: Indonesia: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 47: Indonesia: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 48: Others: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 49: Others: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 50: Europe: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 51: Europe: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 52: Germany: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 53: Germany: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 54: France: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 55: France: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 56: United Kingdom: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 57: United Kingdom: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 58: Italy: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 59: Italy: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 60: Spain: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 61: Spain: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 62: Russia: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 63: Russia: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 64: Others: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 65: Others: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 66: Latin America: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 67: Latin America: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 68: Brazil: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 69: Brazil: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 70: Mexico: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 71: Mexico: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 72: Others: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 73: Others: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 74: Middle East and Africa: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 75: Middle East and Africa: Spine Biologics Market: Breakup by Country (in %), 2023
• Figure 76: Middle East and Africa: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 77: Global: Spine Biologics Industry: SWOT Analysis
• Figure 78: Global: Spine Biologics Industry: Value Chain Analysis
• Figure 79: Global: Spine Biologics Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Spine Biologics Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Spine Biologics Market Forecast: Breakup by Product (in Million US$), 2024-2032
• Table 3: Global: Spine Biologics Market Forecast: Breakup by Surgery Type (in Million US$), 2024-2032
• Table 4: Global: Spine Biologics Market Forecast: Breakup by End User (in Million US$), 2024-2032
• Table 5: Global: Spine Biologics Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 6: Global: Spine Biologics Market: Competitive Structure
• Table 7: Global: Spine Biologics Market: Key Players

The global spine biologics market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.9 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032. The market is driven by the widespread adoption of minimally invasive surgeries (MIS), the growing geriatric population, the growing access to healthcare services on account of inflating income levels, and the increasing incidence of spinal disorders.

Spine Biologics Market Analysis:

Major Market Drivers: The spine biologics market research indicates that the market is primarily driven by the increasing prevalence of spinal disorders such as disc disease and spinal stenosis, often related to aging and lifestyle factors.

Key Market Trends: There is a noticeable trend toward the use of biologics in spine surgeries to promote quicker recovery and better outcomes, aligning with advancements in medical technologies. In the spine biologics market forecast, the industry will witness ongoing innovation with the integration of artificial intelligence and machine learning technologies to enhance the precision and effectiveness of spine biologics.

Geographical Trends: North America currently leads the global market due to its advanced healthcare infrastructure, high healthcare expenditure, and awareness of spinal ailments. Moreover, the Asia-Pacific region is witnessing rapid growth according to the spine biologics market statistics owing to increasing healthcare access, rising economic standards, and a growing geriatric population.

Competitive Landscape: Some of the major market players in the spine biologics industry include Arthrex Inc., Alphatec Holdings Inc., Exactech Inc., Johnson & Johnson, Medtronic plc, NuVasive Inc., Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet, among many others.

Challenges and Opportunities: The challenges in the market include concerns over the high cost of biologic products and stringent regulatory environments that can delay product launches. As outlined in the spine biologics market overview, the growing collaborations with insurance providers and healthcare facilities hold the potential to improve access to and uptake of biologic treatments generating numerous opportunities.

Spine Biologics Market Trends:

Increasing Prevalence of Spinal Disorders

The growing occurrence of spinal disorders is affecting the spine biologics market growth. In addition, the increasing life expectancy, and lifestyle issues, are spurring the development of degenerative illnesses such as disc disease and spinal stenosis. According to the World Health Organization (WHO) in 2020 approximately 1 in 13 individuals equating to 619 million individuals experienced low back pain (LBP), a 60% increase from 1990. It is further estimated that low back pain cases will increase by around 843 million by 2050 which emphasizes the widespread nature of spinal issues. The rising number of incidences is with the age group of 80 years, and the increasing number of LBP cases occur at the age of 50-55 years. This widespread prevalence necessitates ongoing development and deployment of effective treatments, including biologics, which help promote bone growth and healing, making them critical in treating these pervasive conditions.

Rising Adoption of Minimally Invasive Surgeries (MIS)

Minimally invasive surgeries (MIS) for spinal conditions are preferred due to their less distressful nature and quicker recovery times compared to traditional open surgeries. The global market for minimally invasive surgery is projected to expand at a compound annual growth rate (CAGR) of roughly 6% during 2024-2032 as per the IMARC GROUP. It reached US$ 52.9 Billion in 2023 and anticipates the market to reach US$ 91.0 Billion by 2032. This growth is declarative of a shift in surgical methods that reduce hospital stays and recovery periods, which is particularly beneficial for spine biologics market value.

Growing Geriatric Population

The growing geriatric population is driving the spine biologics market demand. As individuals age, the risk of developing spinal disorders increases, necessitating more frequent and intensive care. As per the data from the UNITED NATIONS population aged 65 and over is expected to rise from 10% in 2022 to 16% in 2050. It is forecasted that individuals aged 65 years or above globally will double the number of children under age 5 and will be equal to the number of 12-year-old children. It means a rising number of age-associated spinal conditions, escalating the demand for treatments that are effective and minimally invasive. For instance, biologics, which aid in the natural healing processes, are particularly suited to meet these needs, aligning with the growing healthcare requirements of an aging global population.

Spine Biologics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, surgery type, and end user.

Breakup by Product:

Spinal Allografts

Machined Bones Allograft

Demineralized Bone Matrix

Bone Graft Substitutes

Bone Morphogenetic Proteins

Synthetic Bone Grafts

Cell Based Matrix

Bone graft substitutes account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes spinal allografts (machined bones allograft, demineralized bone matrix), bone graft substitutes, (bone morphogenetic proteins, synthetic bone grafts), and cell-based matrix. According to the report, bone graft substitutes represented the largest segment.

Bone graft substitutes offer an alternative to customary bone grafts, stipulating structural support and facilitating bone healing processes in spinal surgeries. These substitutes embrace synthetic materials, allografts, and demineralized bone matrix, and are advocated for their aptitude to endorse bone fusion and curb the need for harvesting bone from the patient's own body, minimizing surgical complications and recovery time. As per the statistics by IMARC GROUP, the global bone graft and substitute market reached US$3.2 Billion in 2023. It is estimated to reach US$ 5.1 Billion by 2032 with a compound annual growth rate (CAGR) of 5.2% during 2024-2032. Moreover, various advancements in biomaterials, regenerative medicine, and bone graft substitutes are witnessing increasing adoption in spinal procedures, thus positively increasing the spine biologic market value.

Breakup by Surgery Type:

Open Spine Surgery

Minimally Invasive Spine Surgery

Minimally invasive spine surgery holds the largest share of the industry

A detailed breakup and analysis of the market based on the surgery type have also been provided in the report. This includes open spine surgery and minimally invasive spine surgery. According to the report, minimally invasive spine surgery accounted for the largest market share.

Minimally invasive spine surgery is primarily attributed to the growing preference for minimally invasive procedures among patients and healthcare providers. Minimally invasive spine surgery offers several advantages over traditional open surgeries, including smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery times. As a result, it has gained popularity for treating various spinal conditions, such as degenerative disc disease, herniated discs, spinal stenosis, and vertebral fractures. According to the NATIONAL LIBRARY OF MEDICINE, minimally invasive spine (MIS) surgery has advanced significantly with imaging navigation systems, robotics, and endoscopy. More than 400,000 cases are accomplished in the United States annually with spine fusion being the commonly conducted and established treatment options for spine trauma, tumors, structural deformities, and degenerative disorders.

Breakup by End User:

Hospitals

Ambulatory Care Centers

Spinal Surgery Centers

Orthopedic Clinics

Others

Hospitals represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ambulatory care centers, spinal surgery centers, orthopedic clinics, and others. According to the report, hospitals represented the largest segment.

Hospitals are major centers for specialized medical care that attract a considerable proportion of patients seeking treatments for several forms of spinal disorders including those that necessitate surgeries. Furthermore, some hospitals have dedicated spine centers or departments where they offer services, making them the preferred centers for comprehensive source care. Besides this, hospitals have strong collaborations with spine biologic manufacturers and suppliers, thereby enhancing the efficiency of the equipment. In June 2022, Xenco Medical broadened its range of devices for ambulatory surgery centers by securing Food and Drug Administration (FDA) clearance and introducing its Multilevel CerviKit for their single use. It comprises a complete suite of implants and single-use instruments for two, three, and four level procedures of the anterior cervical spine.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest spine biologics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for spine biologics.

North America's dominance in the market can be attributed to highly developed healthcare infrastructure, the high rate of innovative medical technologies' adoption, and a large patient pool with spinal disorders. For instance, as per the data from the National Spinal Cord Injury Association, approximately 450,000 individuals reside in the United States with a spinal cord injury (SCI). Annually, an estimated 17,000 new cases of SCI arise in the U.S., predominantly stemming from trauma to the vertebral column. Thus, the increasing incidence of SCI population is significantly escalating the demand for spine biologics to treat disorders across the region. Additionally, favorable reimbursement policies, strong R&D efforts, and awareness of the advantages of minimally invasive surgical procedures are generating the spine biologics market revenue in North America.

Competitive Landscape:

The spine biologics market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the spine biologics industry include Arthrex Inc., Alphatec Holdings Inc., Exactech Inc., Johnson & Johnson, Medtronic plc, NuVasive Inc., Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

At present, key players in the market are investing in research and innovation to develop models that outperform rivals and offer solutions sought by customers. They also work hard to ensure their products remain in the market and meet customers' demands through the development of strategic alliances, acquisitions, and expansions into new markets to penetrate more markets and meet all customer needs. For instance, in October 2023, Orthofix Medical Inc., a prominent global spine and orthopedics corporation unveiled the full commercial release of OsteoCove, which is an innovative bioactive synthetic graft, following its 510k clearance. It is offered in putty and strip forms, meticulously developed to offer exceptional bone-forming capabilities and optimal handling properties for various spine and orthopedic procedures. Moreover, excellent marketing and brand management also make their products highly demanded, which is providing a positive spine biologics market outlook.

Spine Biologics Market News:

August 2022: Graftys SA announced the renewal of its lengthy contract with Arthrex for a multi-year supply agreement concerning advanced synthetic bone graft materials.

October 2023: Stryker, a prominent medical technology company unveiled their Q guidance system with spine guidance software which was deployed to supply improved surgical planning and navigation in over 2,400 spinal cases.

Key Questions Answered in This Report

• 1. How big is the global spine biologics market?
• 2. What is the expected growth rate of the global spine biologics market during 2024-2032?
• 3. What are the key factors driving the global spine biologics market?
• 4. What has been the impact of COVID-19 on the global spine biologics market?
• 5. What is the breakup of the global spine biologics market based on the product?
• 6. What is the breakup of the global spine biologics market based on the surgery type?
• 7. What is the breakup of the global spine biologics market based on the end user?
• 8. What are the key regions in the global spine biologics market?
• 9. Who are the key players/companies in the global spine biologics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Spine Biologics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Spinal Allografts
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Machined Bones Allograft
    • 6.1.2.2 Demineralized Bone Matrix
  • 6.1.3 Market Forecast
• 6.2 Bone Graft Substitutes
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Bone Morphogenetic Proteins
    • 6.2.2.2 Synthetic Bone Grafts
  • 6.2.3 Market Forecast
• 6.3 Cell Based Matrix
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Surgery Type

• 7.1 Open Spine Surgery
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Minimally Invasive Spine Surgery
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ambulatory Care Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Spinal Surgery Centers
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Orthopedic Clinics
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Arthrex Inc
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 SWOT Analysis
  • 14.3.2 Alphatec Holdings Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Exactech Inc
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Johnson & Johnson
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Medtronic plc
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 NuVasive Inc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Orthofix Medical Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Stryker Corporation
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Wright Medical Group N.V.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 SWOT Analysis
  • 14.3.10 Zimmer Biomet
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis